drugset / Trial / NCT04393311
Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and efficacy of intravenous (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease severity, need for ventilator support, and mortality in patients with COVID 19.
Timeline
- Start
- 2022-02
- Primary completion
- 2022-08
- Completion
- 2022-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulinastatin | Protein / enzyme biologic | 200000 unknown | Intravenous |